- Clinical Pipeline
- Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
- ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
- Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies)
- ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
- ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
- Partnered Products and Programs
- Kisqali®(ribociclib) CDK4/6 inhibitor (Oncology)
- Balversa® (erdafitinib) FGFr inhibitor (Oncology)
- AZD5363 PKB/Akt Inhibitor (Oncology)
- Multiple Targets and Therapeutic Areas
- Pyramid™ Discovery Platform
- Oncology and CNS Discovery
- Sustaining Innovation
Below is our pipeline of investigational compounds that are currently in various stages of clinical development.
| Phase 1 | Phase 2 | Phase 3 |
|---|
Guadecitabine (SGI-110)
DNMT inhibitor (Hematological Malignancies and Solid Tumors)
| . | . | . |
Guadecitabine (SGI-110)
DNMT inhibitor (Relapsed/Refractory AML)
| . | . | . |
Guadecitabine (SGI-110)
DNMT inhibitor (Relapsed/Refractory MDS or CMML)
| . | . | . |
Guadecitabine (SGI-110)
DNMT inhibitor (Solid Tumors)
| . | . |
Decitabine and Cedazuridine (ASTX727)
Oral DNMT inhibitor (Hematological Malignancies)
| . | . | . |
Tolinapant (ASTX660)
Antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP) (Solid Tumors & Lymphomas)
| . | . |
ASTX029
Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
| . |
ASTX295
Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
| . |
Azacitidine and Cedazuridine (ASTX030)
Oral DNMT inhibitor (Hematological Malignancies)
| . |
TAS1440
Oral LSD1 inhibitor (Hematological Malignancies)
| . |
TAS1553
Oral ribonucleotide reductase (RNR) inhibitor (Hematological Malignancies)
| . |